The UK Court of Appeal dismisses the Competition Authority appeal against the Competition Appeal Tribunal ruling quashing fines imposed on two pharmaceutical companies for charging excessive and unfair prices for an anti-epilepsy drug (Pfizer / Flynn)

On 10 March 2020, the UK’s Court of Appeal dismissed the Competition and Market Authority’s (“CMA”) appeal against a 2018 ruling by the Competition Appeals Tribunal (“CAT”) that quashed the CMA’s 2016 fine imposed on Pfizer and Flynn for charging excessive and unfair prices for phenytoin sodium (an anti-epilepsy drug) capsules. Pfizer had originally been fined £ 84.2

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Van Bael & Bellis (Brussels)

Quotation

Tim Kasten, The UK Court of Appeal dismisses the Competition Authority appeal against the Competition Appeal Tribunal ruling quashing fines imposed on two pharmaceutical companies for charging excessive and unfair prices for an anti-epilepsy drug (Pfizer / Flynn), 10 March 2020, e-Competitions May 2020 - II, Art. N° 93999

Visites 24

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues